Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Hum Pathol. 2019 Jul 9;91:114–122. doi: 10.1016/j.humpath.2019.07.004

Table 2.

Renal Cell Carcinoma with Aberrant FH/2SC Expression.

Case No. Age (years) Gender Follow Up (months) Size (cm) pT N M FH IHC 2SC IHC Tumor Type Outcome Associated Neoplasia Including Leiomyomata
4 19 F 44 Bilateral; Right:12, Left:2.5 pT2b N1 M0 Lost Increased, with nuclear & cytoplasmic positivity Papillary renal cell carcinoma (WHO/ISUP Grade3) Dead of disease* No
5 34 M 19 3 pT3a Nx M0 Retained Increased, with nuclear & cytoplasmic positivity Papillary renal cell carcinoma (WHO/ISUP Grade3) Dead of disease No
6 22 M 10 3.8 NA N1 NA Lost Increased, with nuclear & cytoplasmic positivity Unclassified renal cell carcinoma Dead of disease** No
7 66 M 29 12.5 pT3b N1 M0 Lost Increased, with nuclear & cytoplasmic positivity Unclassified renal cell carcinoma Dead of disease*** No
*

Metastasis to the liver was detected, for patient#4, at 11 months of follow up. In addition, family history of maternal death from unspecified cancer at age 40 was documented in this case.

**

Patient 6 developed lumbar metastases 1 month after surgery.

***

Patient#7 developed pulmonary metastases 13 months after surgery.

NA: Not available